abu 29 2010
San Agustín y el final del verano
Empieza el puerto de primera del mes de septiembre con los gastos de libros, cuadernos, material para el curso, uniformes, matrículas en natación, yudo, inglés… Después del verano los dolores de cabeza por los gastos extras. El Ayuntamiento iniciará el nuevo curso no sabemos si con ganas de hacer cosas o con el espíritu de ahorrar, pero seguimos con grandes obras, tanto en Astrabudua, como en Altzaga, como en los accesos a Arriagas y Kukularra.
¿Qué va a pasar cuando vuelva el tráfico al ritmo normal y con la carretera de la ría regulada por semáforo con un único carril?, ¿qué va a pasar con los autobuses que suben y bajan por la carretera a Goikoa y los de Altzaga Ikastola? Por cierto con riesgo de desprendimiento desde hace varios años y sin hacerse un muro de contención.
Lamentablemente en diez días veremos el follón de las carreteras principales regulados por semáforo y con unas obras que en agosto han contado con una presencia simbólica de personas en el tajo y sin personal del municipio y con mínima presencia de mujeres y eso que hay 746 paradas en Erandio.
San Agustín a finales de agosto va marcando el fin de las vacaciones de verano, para quienes pueden tenerlas, porque recordamos a las 1.524 personas en el paro en Erandio según en Ministerio de Trabajo.
Septiembre empieza con futbol, con ciclismo estatal pasando por Euskal Herria (en otras ocasiones lo ha hecho por Iparralde y por Francia), pero ahora se hace por imposición. Empieza con reforma laboral apoyada por el PNV, que se afianza como partido de derechas y defensor del mundo empresarial, contra los trabajadores y trabajadoras. Con negociación de presupuestos estatales, donde volveremos a oir hablar de compra venta en Euskadi. ¿Esta vez por cuanto seremos vendidos?
Ahora el turismo ha mejorado porque la kale borroka ha desaparecido, ahora la gente viene mas segura a Euskadi porque “I need Spain”, perdón que la quema de contenedores ha sido mala leche después de haber erradicado “ese problema” que no resolvía el predecesor de Ares.
Por cierto las jaiak de Astrabu y las de San Agustín, han contado con un recorte por parte del Ayuntamiento, en temas de imagen que habría que pensar si ha servido de algo: ausencia de wateres públicos, falta de decoración del municipio, falta de indicación de ubicaciones de barracas, txosnak y lugares de conciertos. Saliendo del metro de Astrabudua, para quien no es del barrio, no había indicación en los San Lorenzos y en Altzaga, el nuevo paseo TOTALMENTE LIBRE (excepto la churrería), las barracas no se ven, las txonas y los lugares de concierto escondidos.
Pero algo ha mejorado en el municipio, la venta ambulante se ha institucionalizado, el Ayuntamiento cobra por los puestos de venta de CDs y DVDs piratas, copias de bolsos, de ropa y de cinturones… habrá que cambiar la fiesta y decir que es la fiesta de la venta libre.
Menos mal que la gente joven sigue siendo alternativa y organiza cosas aunque sea sin el apoyo del Ayuntamiento. Ayer tuvimos concurso de putxeras y de bacalao al mismo tiempo, hoy domingo fin de fiestas. Para ver fuegos artificiales ya tenemos los de Bilbo, porque en Erandio no hay.
Por cierto, el otro día me comentaban como había alguna cuadrilla en los San Roques de Portu que portaban en sus camisetas la frase: “Eres mas vago que el hijo de Lalo”. Para quien no sepa quien es el hijo de Lalo, es un tal Francisco que ha dejado de vivir en Portu para ir a vivir a Gasteiz,
Etiquetas todos los blogs: carretera ; Erandio ; Jaiak ; kale borroka ; obras ; paro ; PNV ; presupuestos ; reforma laboral ;
Información Bitacoras.com…
Valora en Bitacoras.com: Empieza el puerto de primera del mes de septiembre con los gastos de libros, cuadernos, material para el curso, uniformes, matrículas en natación, yudo, inglés… Después del verano los dolores de cabeza por los gastos extr…
Que diferencia entre el padre y el hijo. El hijo no ha estudiado porque requiere mucho esfuerzo.
Es mejor posar para la foto y coger el twiter para decir que está cerca del pueblo.
Ojala que la juventud empiece a hacer cosas y nos pase por la izquierda.
priligy premature ejaculation pills Pathiraja P Dhar S Haldar K
Good day! Do you know if they make any plugins to help with SEO?
I’m trying to get my site to rank for some targeted keywords but I’m not seeing very good gains.
If you know of any please share. Thank you!
I saw similar blog here: Warm blankets
Command your army and conquer the battlefield! Lucky Cola
… [Trackback] …
[...] Read More on on that Topic: erandio.euskoalkartasuna.net [...] …
PHF8 knockdown increased T DM1 induced apoptosis and the addition of IL 6 counteracted the induction of apoptosis Fig get cheap cytotec pills
… [Trackback] …
[...] Info to that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] Here you can find 56355 more Info on that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] Info to that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] Information on that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] Read More on that Topic: erandio.euskoalkartasuna.net [...] …
Anavar Guide: Benefits, Dosage, & Bodybuilding Insights
Quick Links
Anavar Guide for Bodybuilding: Benefits, Side Effects,
Dosage, Cycles, & More
Table of Contents
What is Anavar?
How Does Anavar Work?
Increase protein synthesis
Reducing sex hormone-binding globulin levels
Inhibit glucocorticoid hormones
Anavar Benefits for Bodybuilding
Increases lean muscle mass
Promotes Weight Gain in Burn and Injury Recovery
Boosts Strength
Increases Nitrogen Retention
Reduce Pain
Anavar Bodybuilding Dosage
Anavar Side Effects
Conclusion
Frequently Asked Questions (FAQs)
Leave a Reply
Popular Article
Follow Us
Major Links
Trending News
Best SARMs for Cutting, Bulking, Muscle Growth, and Fat Loss in Bodybuilders and
Athletes
Flmodafinil Review – Is This Smart Drug Better Than Modafinil?
SARMs Before And After: 14 Photos of User Cycle Results
Menu
Newsletter
—
Quick Links
Overview of Anavar
Key benefits for bodybuilders
Dosage recommendations
Common side effects
Frequently asked questions
Anavar Guide for Bodybuilding: Benefits, Side Effects, Dosage, Cycles,
& More
Anavar (Oxandrolone) is a synthetic anabolic steroid
derived from dihydrotestosterone. It gained popularity in the 1960s and 1970s as a performance enhancer and has since become
a staple for athletes seeking lean muscle gains without excessive water retention or significant hormonal disruption.
—
Table of Contents
What is Anavar?
How Does Anavar Work?
- Increase protein synthesis
- Reducing sex hormone-binding globulin levels
- Inhibit glucocorticoid hormones
Anavar Benefits for Bodybuilding
- Increases lean muscle mass
- Promotes Weight Gain in Burn and Injury Recovery
- Boosts Strength
- Increases Nitrogen Retention
- Reduce Pain
Anavar Bodybuilding Dosage
Anavar Side Effects
Conclusion
Frequently Asked Questions (FAQs)
What is Anavar?
Anavar, chemically known as 17α-methyl-19-nortestosterone,
was first introduced by the pharmaceutical company Pfizer in 1962.
It is a modified form of testosterone that resists
metabolism by the liver, allowing it to remain active longer.
Unlike many other anabolic steroids, Anavar has a low androgenic profile,
meaning it produces fewer masculinizing effects such as acne or hair loss.
—
How Does Anavar Work?
Anavar’s effectiveness stems from its interaction with cellular mechanisms that promote muscle growth and recovery.
The three primary pathways include:
Increase protein synthesis
The drug binds to androgen receptors in muscle cells, triggering a cascade of events that enhance the translation of mRNA
into proteins. This leads to a higher rate of new muscle fiber formation and
repair.
Reducing sex hormone-binding globulin levels
Sex hormone‑binding globulin (SHBG) normally attaches to testosterone,
rendering it inactive. Anavar lowers SHBG production in the liver, thereby increasing the free fraction of testosterone available for anabolic processes.
Inhibit glucocorticoid hormones
Glucocorticoids like cortisol break down muscle tissue during stress or recovery periods.
By inhibiting cortisol’s activity, Anavar preserves existing muscle mass and speeds up post‑exercise repair.
—
Anavar Benefits for Bodybuilding
Anavar offers a range of advantages that appeal to athletes at
all levels:
Increases lean muscle mass
Users often report noticeable gains in muscular density without the bloating commonly associated with
other steroids. The effect is especially pronounced when combined with a protein‑rich diet
and resistance training.
Promotes Weight Gain in Burn and Injury Recovery
Because Anavar enhances nitrogen retention, it helps
patients recovering from burns or severe injuries regain lean body mass
more quickly than standard rehabilitation protocols.
Boosts Strength
Many athletes find that their maximal lifts improve by 5–10% during a typical 6‑to‑8
week cycle. This strength boost is attributable to the drug’s
influence on muscle fiber cross‑sectional area and improved neuromuscular efficiency.
Increases Nitrogen Retention
By keeping nitrogen in the bloodstream, Anavar ensures that amino acids are available for
protein synthesis. This reduces catabolism and supports muscle growth even during caloric deficits.
Reduce Pain
Users have reported a reduction in joint discomfort and inflammation, likely
due to the anti‑glucocorticoid activity of the compound.
This can lead to more consistent training sessions without the usual
soreness that follows heavy lifts.
—
Anavar Bodybuilding Dosage
Dosage varies depending on goals, experience
level, and whether the user is male or female.
Typical guidelines include:
Male cycles: 20–40 mg per day for 6–8 weeks.
Female cycles: 5–10 mg per day for 4–6 weeks.
It’s common to start at a lower dose and increase gradually, monitoring how the body responds.
A post‑cycle therapy (PCT) may be recommended after extended use or high dosages to help restore natural hormone production.
Anavar Side Effects
While considered relatively mild compared to other
anabolic steroids, Anavar still carries risks:
Liver strain: As a 17α‑alkylated steroid, it can increase liver enzyme levels.
Hormonal imbalance: Suppression of the hypothalamic‑pituitary‑gonadal axis may occur, especially with high doses or
prolonged use.
Cardiovascular changes: Alterations in cholesterol profiles can elevate LDL and lower HDL in some users.
Hair loss and acne: Though less common than with stronger steroids,
these effects can still manifest.
Regular monitoring of liver enzymes and lipid panels is advised for anyone considering a cycle.
Conclusion
Anavar remains a favored choice among bodybuilders seeking
lean muscle gains, strength improvements, and reduced water retention. Its
mechanism of action—boosting protein synthesis while curbing catabolic hormones—provides tangible benefits without the
severe side effects associated with many other
anabolic agents. Proper dosing, careful monitoring,
and adherence to safe cycling practices can help maximize results while minimizing health risks.
—
Frequently Asked Questions (FAQs)
Q1: Can I use Anavar if I’m a novice lifter?
A1: Yes, but start on the lower end of the dosage spectrum (10–20 mg per day for
men) and observe how your body reacts before increasing.
Q2: Is Anavar legal for recreational use in most countries?
A2: It is prescription‑only medication. Use outside a medical context may be illegal and carries health risks.
Q3: How long does it take to see results?
A3: Many users notice changes within 4–6 weeks, though significant gains typically appear after 8–12 weeks of
consistent training and proper nutrition.
Q4: Can I combine Anavar with other supplements or steroids?
A4: It is possible but increases the risk of side effects.
Consulting a qualified professional before combining agents is essential.
Q5: What should I do if I experience liver strain while on Anavar?
A5: Stop usage immediately, consult a healthcare provider, and have
liver function tests performed. Avoid further hepatotoxic substances during recovery.
Dianabol Drug Information, Uses, Side Effects, Chemistry
**A concise guide for research teams on how
to design, run, and publish a study that meets scientific rigor, ethical standards,
and regulatory compliance**
| **Step** | **What you need to do** | **Why it matters** |
**Key resources / guidance** |
|———-|————————|——————–|——————————|
| 1. Define the *scientific question* & *hypothesis* | Write
a clear, testable hypothesis that addresses a
gap in knowledge and is specific enough for the study design you plan to use.
| A strong hypothesis drives every subsequent decision (sample size, variables,
analysis). | - CONSORT: “Planning a clinical trial”
- NIH Blueprint for Clinical Research |
| 2. Choose an *appropriate study design* (RCT, cohort, case‑control, etc.) | Match the question to a design that can answer
it while minimizing bias and maximizing feasibility.
| The design determines how you’ll collect data, control confounders, and analyze
results. | - STROBE for observational studies
- TREND for non‑randomized trials |
| 3. Conduct *sample size calculation* (power analysis)
using estimated effect size, alpha, power, attrition.
| Ensure enough participants to detect a clinically meaningful difference with acceptable Type
I/II error rates. | Under‑powered studies risk false negatives; over‑powered waste resources and may detect trivial
differences. | Use software like G*Power or statistical packages (R, Stata).
|
| 4. Develop *randomization scheme* if applicable: block
randomization, stratified blocks, permuted blocks.
| Balance known prognostic factors across arms to reduce
bias. | Improper randomization can introduce allocation imbalance and threaten internal validity.
| Implement via computer-generated lists or central randomization services.
|
| 5. Define *allocation concealment* mechanism (sealed opaque envelopes, centralized web‑based system).
| Prevent selection bias by ensuring investigators cannot
predict upcoming assignment. | Without proper concealment,
researchers may influence enrollment based on expected allocation. |
| 6. Draft the *protocol* including inclusion/exclusion criteria, intervention details, schedule of visits, safety monitoring plan, data collection methods, statistical analysis plan, and governance structure.
| Provides a detailed roadmap for investigators and regulators; ensures consistency across sites.
| Protocol deviations can compromise data integrity and lead to
regulatory scrutiny. |
| 7. Obtain *ethical approval* from institutional review
boards (IRBs)/ethics committees at all participating centers.
| Protects participant rights and safety; mandatory for publication and funding.
| Failure to secure IRB approval may result in trial suspension or
retraction of results. |
| 8. Register the study on a public registry (e.g., ClinicalTrials.gov, EU Clinical Trials Register).
| Enhances transparency; required by many journals and
funding agencies. | Unregistered trials face criticism
for potential selective reporting. |
—
### 2. Regulatory Pathways
| **Regulatory Body** | **Primary Focus** | **Key Requirements for Clinical Trial** |
|———————|——————-|——————————————|
| **FDA (USA)** | Ensures safety and efficacy of drugs, biologics, and
devices. | IND submission: preclinical data,
manufacturing details, investigator’s brochure; periodic reporting; adverse
event monitoring; final NDA or BLA review.
|
| **EMA (EU)** | Harmonizes drug approval across member states;
oversees clinical trial authorization. | Clinical Trial Application (CTA) to
national competent authority; Data Protection Authority (DPA) notification; EMA scientific advice
for protocol design. |
| **Health Canada** | Safeguards public health through rigorous assessment
of medical products. | Clinical Trial Application (CTA) and Clinical Study Report (CSR); ongoing reporting; submission of New Drug Submission (NDS).
|
| **FDA (US)** | Protects consumers by ensuring safety, efficacy, and quality of drugs, biologics, and devices.
| Investigational New Drug (IND) application; Institutional Review Board (IRB) approval;
Clinical Trial Authorization; Periodic Safety Update
Reports (PSUR). |
These agencies operate under a set of internationally recognized
principles that ensure consistency, transparency, and ethical
rigor across the globe.
—
## 2. Core Principles Guiding International Medical Research
| Principle | Definition | Key Elements |
|———–|————|————–|
| **Scientific Validity** | Ensures that studies are
designed to answer relevant questions reliably and meaningfully.
| Adequate sample size, appropriate methodology,
control of confounding variables. |
| **Human Subject Protection** | Safeguards the
rights, safety, dignity, and welfare of participants.
| Informed consent, privacy/confidentiality, risk minimization. |
| **Transparency & Accountability** | Open reporting and oversight to
foster trust and reproducibility. | Public protocols, data sharing,
conflict-of-interest disclosure. |
These principles are interdependent: rigorous science cannot exist without
ethical conduct; ethical research demands transparency.
—
## 2. The “Human Subject” Definition in the
U.S. Context
### 2.1 Original Scope (1979)
- **Regulation**: 45 CFR §46.102
- **Definition**: Any individual from whom data are obtained through:
- *Interviews, questionnaires, or observation*; **or**
- *Biospecimen collection or tissue sampling*.
- **Implication**: Covered most behavioral and biomedical research.
### 2.2 Current Scope (2020)
| Category | Original Definition | Current Definition |
|———-|———————|——————–|
| **Human Subject** | Any individual who participates in a
study via interview, questionnaire, observation, or biospecimen/tissue collection. | Same as original;
no expansion. |
#### Impact of the Change
- **No Expansion**: The definition has remained unchanged.
- **Resulting Scope**:
- Studies involving only anonymous data, public
datasets, or purely computational simulations without direct interaction with human subjects
are *not* considered “human subject” research under this
definition.
- However, if such studies use personally identifiable information (PII) or data that could be linked back to individuals, they may still fall under
other regulatory frameworks (e.g., GDPR, HIPAA),
but not the specific “human subject” category.
—
### 4. Summary of Regulatory Scope
| **Regulation** | **Triggering Condition** | **Typical Study
Types Covered** |
|—————-|————————–|———————————|
| FDA – Investigational New Drug (IND) | Human clinical trial with investigational drug or biologic |
Phase I–III trials, dose‑finding studies, safety evaluations |
| FDA – Investigational Device Exemption (IDE)
| Clinical study of a medical device not yet cleared | Early‑stage
implant trials, diagnostic imaging studies |
| FDA – IND/IDE Not Required | Use of an already approved drug/device in a
new context | Retrospective chart reviews, observational cohort studies |
**Key Takeaway:**
- **IND/IDE mandatory** only when the study involves *investigational* products or *new indications* for approved items.
- For *retrospective*, *observational*, or *standard‑of‑care*
investigations using *approved* drugs/devices, no IND/IDE is required.
—
## 2. Regulatory Frameworks and How They Apply
| **Regulation / Guidance** | **Scope** | **Relevance to Retrospective Study (Approved Drug)** |
|—————————|———–|—————————————————–|
| **21 CFR Part 312 – Investigational New Drug (IND) Application** | New drugs,
biologics, or medical devices not yet approved by FDA. | Not applicable if drug is already FDA‑approved and used in standard care.
|
| **21 CFR Part 314 – Current Good Manufacturing Practice (CGMP)**
| Ensures quality of drug manufacturing. | No effect on retrospective data analysis.
|
| **21 CFR Part 56 – Institutional Review Board (IRB) Requirements** | Human subjects research oversight.
| Applies to any study involving patient data; IRB must approve
or waive review. |
| **45 CFR Part 46 – Common Rule (Protection of Human Subjects)** | Ethical standards for human subject research, including informed consent.
| Applies if patient data is used without de‑identification; may require waiver of consent for retrospective chart reviews.
|
| **HIPAA Privacy Rule (45 CFR Part 164.530-540)** | Protects PHI and sets rules for its use in research.
| Requires either de‑identified data or a HIPAA authorization/waiver.
|
| **Office for Civil Rights (OCR) Enforcement** | Enforces compliance with HIPAA and Common Rule.
| Non‑compliance can lead to civil penalties. |
—
## 2. Regulatory Pathways for Using Patient Data
### A. De‑Identified Data (Safe Harbor Method)
| Step | Action |
|——|——–|
| **1. Remove PHI** | Delete all 18 identifiers: names, geographic data below the state level,
all dates (except year), and any other unique codes that could identify
a patient. |
| **2. Verify Safe Harbor Criteria** | Ensure no individual can be identified through these remaining data
elements or by combining them with external information. |
| **3. Document De‑identification** | Create an audit trail:
date of de‑identification, list of removed fields,
and the methodology used. |
| **4. Use Data** | The dataset is fully compliant; no
further approvals required for research involving this data.
|
### 2b) Using HIPAA “Limited Data Set” (LDS)
If you need to retain dates or other identifiers that are not
allowed in a public release, the data must be treated
as a Limited Data Set.
| Step | Action |
|——|——–|
| **1. Define LDS** | Confirm that the dataset includes only those
elements permitted:
• Dates (but not year of death)
• Geographic subdivisions > 3 digits
• Names, phone numbers, email addresses excluded. |
| **2. Sign a Data Use Agreement (DUA)** | The holder must sign a formal DUA that specifies:
- Purpose and scope of use.
- Restrictions on further disclosure.
- Security measures.
- Obligation to return or destroy data after project completion. |
| **3. Ensure compliance with HIPAA** | Verify that
the dataset is either:
• De-identified under §164.514(b) (all identifiers
removed), or
• Covered by a Business Associate Agreement if it contains
PHI. |
| **4. Data storage and security** | Implement appropriate safeguards
(encryption, access controls). |
| **5. Reporting obligations** | If any data breach occurs, report per HIPAA Breach Notification Rule.
|
Thus, the correct answer is **B: B** – you must
provide an explanation of each required compliance step.
—
### 4. Final Output
“`
A
B
“`
These are the two letters that correctly respond guide to using dianabol cycle 20mg the
four questions in order.
best legal peds
References:
http://www.udrpsearch.com